CreatorsPublishersAdvertisers

#Height

endocrine.org

Phase 3 Trial Shows Lonapegsomatropin Is Superior to Somatropin in Treatment-Naïve Children with Growth Hormone Deficiency

The investigational long-acting, once-weekly prodrug lonapegsomatropin (TransCon hGH) may be more beneficial to treatment-naïve pediatric patients with growth hormone deficiency (GHD) than daily somatropin of equivalent weekly dose, according to a paper recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Aimee D. Shu, MD, of...
HEALTH
Monthly Prescribing Reference

Skytrofa, a Once-Weekly Therapy for Pediatric Growth Hormone Deficiency, Now Available

Skytrofa® (lonapegsomatropin-tcgd) is now available for the treatment of patients 1 year of age and older weighing at least 11.5kg with growth failure due to inadequate secretion of endogenous growth hormone. Skytrofa is a long-acting prodrug of the human growth hormone, somatropin, produced by recombinant DNA technology using E. coli....
HEALTH
Picture for Skytrofa, a Once-Weekly Therapy for Pediatric Growth Hormone Deficiency, Now Available
TRENDING TOPICS
YOU MAY ALSO LIKE